Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform into pharmacies in North Central London, marking the second NHS Integrated Care Board (ICB) to adopt this initiative aimed at addressing health inequalities through cholesterol screening [1][2] - The expansion will enhance access to preventative testing for underserved populations, aligning with the UK's vision for a more agile and accessible healthcare system [2][3] - The initiative is part of a broader strategy to transform community pharmacies into hubs for chronic disease prevention and management, empowering pharmacists to play a crucial role in patient care [3][4] Company Overview - Avricore Health Inc. focuses on developing early-stage technologies to advance pharmacy practice and patient care, with HealthTab™ as its flagship offering [14] - The HealthTab™ system provides rapid, lab-accurate results for various biomarkers, facilitating the management of chronic diseases such as diabetes and heart disease [12][13] - The company aims to create the world's largest network of rapid testing devices in community pharmacies, enhancing patient access to actionable health information [14] Industry Context - The UK's NHS Pharmacy First program and recent cardiovascular disease screening initiatives reflect a commitment to a decentralized, patient-centric model of care [6] - Community-based cardiovascular disease screening has been identified as a high-return healthcare investment, with reported returns of £7.52 for every £1 spent on screening [9] - The integration of HealthTab™ with Patient Knows Best (PKB) enhances patient engagement by allowing real-time test results to be incorporated into personal NHS health records [10][11]